Q-omics provides the consensus-scored OLFML2A profile across patient tissues and cancer cell-line models. OLFML2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OLFML2A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, OLFML2A RNA expression shows 16,530 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where OLFML2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OLFML2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OLFML2A survival associations across molecular data types. OLFML2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OLFML2A RNA expression–survival associations across cancer types. High OLFML2A expression shows unfavorable associations in MESO, SKCM, KIRP, BLCA and STAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OLFML2A RNA expression.
This table summarizes OLFML2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OLFML2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OLFML2A shows lower tumor expression in BLCA, COAD and UCEC and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher OLFML2A RNA expression in tumor versus normal tissue (log2 FC = +2.729, t-test p < 0.001).
This table shows molecular features associated with OLFML2A in patient tissues and cancer cell lines. In patient samples, OLFML2A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OLFML2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
